Lannett gets FDA nod for clinical trial of biosimilar insulin glargine
Lannett Company has been given clearance from the US Food and Drug Administration (FDA) to proceed with a clinical trial of biosimilar insulin glargine. The FDA clearance follows the completion of the regulator’s safety review of the investigational new drug (IND) application for the biosimilar. Lannett is co-developing biosimilar insulin glargine with its alliance partners […]